torcetrapib

^[1]^[2]^[3]^[4]^[5]^[6]

Indications

10-120 mg PO BID

(reported in clinical trials)

inhibition of cholesteryl ester transfer protein
increases HDL cholesterol by 16-91% (dose-dependent)^[3]
- 61% for dose of 120 mg BID in combination with 20 mg of atorvastatin QD^[1]
- despite increasing HDL, increases cardiovascular events & all-cause mortality^[6]
reduces LDL cholesterol 17% in combination with atorvastatin

↑ ^1.0 ^1.1 Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004 Apr 8;350(15):1505-15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15071125
↑ Brewer HB Jr. Increasing HDL Cholesterol Levels. N Engl J Med. 2004 Apr 8;350(15):1491-4. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15071124
↑ ^3.0 ^3.1 Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. Epub 2004 Jan 22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14739125
↑ Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003 Nov;4(11):1901-38. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14596646
↑ Prescriber's Letter 11(5):27 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200504&pb=PRL (subscription needed) http://www.prescribersletter.com
↑ ^6.0 ^6.1 ^6.2 Barter PJ et al, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17984165